Travere Therapeutics (TVTX) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Travere Therapeutics Revenue Highlights

Latest Revenue (Y)

$233.18M

Latest Revenue (Q)

$62.90M

Main Segment (Y)

License

Travere Therapeutics Revenue by Period

Travere Therapeutics Revenue by Year

Date	Revenue	Change
2024-12-31	$233.18M	60.55%
2023-12-31	$145.24M	-31.50%
2022-12-31	$212.02M	-6.80%
2021-12-31	$227.49M	14.71%
2020-12-31	$198.32M	13.11%
2019-12-31	$175.34M	6.75%
2018-12-31	$164.25M	6.01%
2017-12-31	$154.94M	15.98%
2016-12-31	$133.59M	33.74%
2015-12-31	$99.89M	254.19%
2014-12-31	$28.20M	100.00%
2013-12-31	-	100.00%
2012-12-31	-	100.00%
2012-02-29	-	100.00%
2011-02-28	-	100.00%
2010-02-28	-	100.00%
2009-02-28	-	-

Travere Therapeutics generated $233.18M in revenue during NA 2024, up 60.55% compared to the previous quarter, and up 132.99% compared to the same period a year ago.

Travere Therapeutics Revenue by Quarter

Date	Revenue	Change
2024-09-30	$62.90M	16.23%
2024-06-30	$54.12M	30.80%
2024-03-31	$41.37M	-8.18%
2023-12-31	$45.06M	21.47%
2023-09-30	$37.09M	-37.86%
2023-06-30	$59.70M	4.74%
2023-03-31	$56.99M	2.01%
2022-12-31	$55.87M	4.43%
2022-09-30	$53.50M	-1.24%
2022-06-30	$54.17M	11.71%
2022-03-31	$48.49M	-15.31%
2021-12-31	$57.25M	-16.08%
2021-09-30	$68.22M	24.90%
2021-06-30	$54.62M	15.21%
2021-03-31	$47.41M	-7.01%
2020-12-31	$50.98M	-0.31%
2020-09-30	$51.14M	5.59%
2020-06-30	$48.43M	1.38%
2020-03-31	$47.77M	2.32%
2019-12-31	$46.69M	5.21%
2019-09-30	$44.37M	-0.75%
2019-06-30	$44.71M	12.98%
2019-03-31	$39.57M	-9.60%
2018-12-31	$43.77M	7.53%
2018-09-30	$40.71M	-1.53%
2018-06-30	$41.34M	7.56%
2018-03-31	$38.43M	-8.88%
2017-12-31	$42.18M	4.55%
2017-09-30	$40.34M	3.97%
2017-06-30	$38.80M	15.41%
2017-03-31	$33.62M	-9.93%
2016-12-31	$37.33M	9.96%
2016-09-30	$33.95M	1.90%
2016-06-30	$33.31M	14.83%
2016-03-31	$29.01M	-4.73%
2015-12-31	$30.45M	8.72%
2015-09-30	$28.00M	16.36%
2015-06-30	$24.07M	38.55%
2015-03-31	$17.37M	23.34%
2014-12-31	$14.08M	68.71%
2014-09-30	$8.35M	45.40%
2014-06-30	$5.74M	20479.69%
2014-03-31	$27.90K	100.00%
2013-12-31	-	100.00%
2013-09-30	-	100.00%
2013-06-30	-	100.00%
2013-03-31	-	100.00%
2012-11-30	-	100.00%
2012-08-31	-	100.00%
2012-05-31	-	100.00%
2012-02-29	-	100.00%
2011-11-30	-	100.00%
2011-08-31	-	100.00%
2011-05-31	-	100.00%
2011-02-28	-	100.00%
2010-11-30	-	100.00%
2010-08-31	-	100.00%
2010-05-31	-	-

Travere Therapeutics generated $62.90M in revenue during Q3 2024, up 16.23% compared to the previous quarter, and up 105.36% compared to the same period a year ago.

Travere Therapeutics Revenue Breakdown

Travere Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
License	$6.47M	$17.70M	-	-	-
Royalty	$600.00K	-	-	-	-
Active Pharmaceutical Ingredient	-	$3.30M	-	-	-
Tiopronin Products	-	-	$97.97M	$115.12M	$108.88M
Product	-	-	$200.53M	$210.78M	-
Bile Acid Products	-	-	$102.56M	$95.65M	$89.44M

Travere Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: License (91.51%), and Royalty (8.49%).

Quarterly Revenue by Product

Product/Service	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20
License	$1.24M	$1.90M	$1.94M	$1.39M	$14.54M	$3.16M	$2.67M	-	-	-	-	-	-	-	-	-	-	-	-	-
Product	-	$61.00M	$52.18M	$39.98M	$57.01M	$50.28M	$52.34M	$50.79M	$50.95M	$46.44M	$54.58M	$54.17M	-	-	-	-	-	-	-	-
Active Pharmaceutical Ingredient	-	-	-	-	-	$3.30M	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Bile Acid Products	-	-	-	-	-	-	$27.50M	$26.11M	$26.53M	$25.42M	$25.53M	$25.07M	$24.35M	$24.97M	$21.96M	$22.67M	$22.91M	$21.57M	$22.28M	-
Tiopronin Products	-	-	-	-	-	-	$26.05M	$21.17M	$25.82M	$25.37M	$25.42M	$21.37M	$29.82M	$29.64M	$25.44M	$28.31M	$28.23M	$26.86M	$25.49M	-

Travere Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: License (100.00%).

Travere Therapeutics Revenue Breakdown by Country

Quarterly Revenue by Country

Country	Mar 22
FRANCE	$8.00M

Travere Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 22: FRANCE (100.00%).

Travere Therapeutics Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
APLS	Apellis Pharmaceuticals	$709.95M	$176.57M
LEGN	Legend Biotech	$285.14M	$93.99M
TVTX	Travere Therapeutics	$233.18M	$62.90M
ANAB	AnaptysBio	$91.28M	$30.02M
STOK	Stoke Therapeutics	$36.55M	$4.89M
MGTX	MeiraGTx	$33.28M	$10.91M
CYTK	Cytokinetics	$18.47M	$463.00K
RNA	Avidity Biosciences	$10.90M	$2.04M
IDYA	IDEAYA Biosciences	$7.00M	-
KROS	Keros Therapeutics	$3.55M	$37.00K
GPCR	Structure Therapeutics	-	-
AKRO	Akero Therapeutics	-	-
PTGX	Protagonist Therapeutics	-	$4.67M
VTYX	Ventyx Biosciences	-	-
PCVX	Vaxcyte	-	-
NUVL	Nuvalent	-	-
COGT	Cogent Biosciences	-	-
RVMD	Revolution Medicines	-	-

TVTX Revenue FAQ

What is Travere Therapeutics’s yearly revenue?

Travere Therapeutics's yearly revenue for 2024 was $233.18M, representing an increase of 60.55% compared to 2023. The company's yearly revenue for 2023 was $145.24M, representing a decrease of -31.50% compared to 2022. TVTX's yearly revenue for 2022 was $212.02M, representing a decrease of -6.80% compared to 2021.

What is Travere Therapeutics’s quarterly revenue?

Travere Therapeutics's quarterly revenue for Q3 2024 was $62.9M, a 16.23% increase from the previous quarter (Q2 2024), and a 69.56% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $54.12M, a 30.80% increase from the previous quarter (Q1 2024), and a -9.35% decrease year-over-year (Q2 2023). TVTX's quarterly revenue for Q1 2024 was $41.37M, a -8.18% decrease from the previous quarter (Q4 2023), and a -27.41% decrease year-over-year (Q1 2023).

What is Travere Therapeutics’s revenue growth rate?

Travere Therapeutics's revenue growth rate for the last 3 years (2022-2024) was 9.98%, and for the last 5 years (2020-2024) was 17.57%.

What are Travere Therapeutics’s revenue streams?

Travere Therapeutics's revenue streams in c 24 are License, and Royalty. License generated $6.47M in revenue, accounting 91.51% of the company's total revenue, down -63.46% year-over-year. Royalty generated $600K in revenue, accounting 8.49% of the company's total revenue

What is Travere Therapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Travere Therapeutics was License. This segment made a revenue of $6.47M, representing 91.51% of the company's total revenue.